Illumina (NASDAQ:ILMN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Illumina (NASDAQ:ILMN) from a hold rating to a buy rating in a research note published on Saturday morning.

A number of other equities research analysts have also commented on the stock. Cowen reissued a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. TD Cowen raised their price target on shares of Illumina from $115.00 to $140.00 and gave the company a “hold” rating in a report on Wednesday, January 7th. Guggenheim upped their price objective on Illumina from $114.00 to $144.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Finally, Canaccord Genuity Group lifted their target price on Illumina from $112.00 to $130.00 and gave the company a “hold” rating in a research note on Monday, December 22nd. Five equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Illumina presently has a consensus rating of “Hold” and an average target price of $122.56.

Illumina Trading Down 2.5%

Shares of Illumina stock opened at $141.65 on Friday. Illumina has a 12-month low of $68.70 and a 12-month high of $151.34. The stock has a market capitalization of $21.64 billion, a P/E ratio of 31.76, a price-to-earnings-growth ratio of 2.35 and a beta of 1.41. The company has a 50-day simple moving average of $132.83 and a 200 day simple moving average of $111.87. The company has a quick ratio of 1.12, a current ratio of 1.43 and a debt-to-equity ratio of 0.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The company’s quarterly revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Research analysts expect that Illumina will post 4.51 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Scott Gottlieb purchased 500 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was purchased at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the transaction, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Scott M. Davies sold 323 shares of the stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.17% of the stock is owned by company insiders.

Institutional Investors Weigh In On Illumina

A number of large investors have recently modified their holdings of the business. Board of the Pension Protection Fund acquired a new position in Illumina during the fourth quarter worth about $26,000. Parkside Financial Bank & Trust lifted its stake in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares in the last quarter. Quent Capital LLC acquired a new position in shares of Illumina during the 3rd quarter worth approximately $29,000. Quarry LP acquired a new position in shares of Illumina during the 3rd quarter worth approximately $32,000. Finally, Aster Capital Management DIFC Ltd purchased a new stake in shares of Illumina in the third quarter valued at approximately $33,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.